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Abstract Obese Zucker diabetic fatty (ZDF) rats are used
as a type-2 diabetes model for microvascular complica-
tions. In order to study retinopathy in this model, changes
in retinal vasculature were analyzed by quantitative mor-
phometry and related to retinal expression of 46 selected
genes that were analyzed by microfluidic card PCR tech-
nology. At 3 months of age, obese animals had developed
stable hyperglycemia (20.7 ± 1.3 mmol/L plasma glucose
vs. 6.5 ± 0.1 mmol/L in lean). Hyperinsulinemia initially
presented in obese rats at 2 months (10.5 ± 0.7 lg/L
plasma insulin vs. 0.2 ± 0.04 lg/L in lean) and decreased
at 3 months (3.9 ± 0.6 vs. 0.5 ± 0.09 lg/ml in lean). At
8 months of age, animals had developed microvascular
complications. An increased number of acellular capillaries
in obese (24 ± 5/mm2) versus lean (15 ± 4/mm2) and a
decreased number of retinal pericytes in obese
(2,270 ± 250/mm2) versus lean animals (1,620 ± 243/
mm2) could be observed. VEGFa, MIF, and HIF-1a were
the most abundantly expressed and inflammatory genes
such as TNFa and IL-6 are the least abundantly expressed
genes. None of these genes were differentially regulated.
Surprisingly, specific growth factors such as bFGF (FGF2)
and placental growth factor, and adhesion molecules such as
ICAM-1 were abundantly expressed and up-regulated in
diabetic versus non-diabetic ZDF rats. In summary, we
observed in type-2 diabetic ZDF rats retinopathy with retinal
vasoregression along with a simultaneous up-regulation of
specific growth factors such as bFGF and adhesion mole-
cules, but only minor changes in key inflammatory genes.
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Introduction
Diabetic retinopathy is a major complication of diabetes
and observed in nearly all individuals with type-1 diabetes
and in more than 80 % of individuals with type-2 diabetes
after 20 years of disease. High glucose levels damage in
particular the retina of diabetic patients and involve small
vessel vasoregression and pericyte loss as initiating pro-
cesses. However, although hyperglycemia is the most
important single factor, it explains only partially the overall
damage as indicated by results from large clinical trials [1].
Rodent animal models recapitulate incipient retinal
damage, including vasoregression. However, most of the
rodent models still build on chemical or genetically
induced destruction of the pancreas, mimicking type-1
diabetes. Male obese Zucker diabetic fatty (ZDF) rats are a
genetic model of type-2 diabetes, mostly used for the
characterization of diabetic nephropathy, whereas retinop-
athy is described still incompletely. Danis and Yang
demonstrated in retina of diabetic ZDF rats modestly
increased numbers of cellular nuclei and an increased
basement membrane thickness [2, 3]. An increased number
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of retinal acellular capillaries (AC) and apoptotic pericytes
and endothelial cells were identified in aged diabetic ZDF
rats and partially reduced by long-term treatment with a
tumor necrosis alpha (TNFa) scavenger [4]. TNFa also
mediated diabetes increased translocation of FOXO1 to
nuclei in microvascular cells in vivo [5]. Up-regulation of
retinal expression of TNFa, but also other markers of
inflammation could be demonstrated in 14-week-old obese
versus lean ZDF rats [6].
Inflammation may be an important disease mechanism
in diabetes, and obese ZDF rats develop local and systemic
inflammation with increased levels of circulating inflam-
matory biomarkers and increased infiltration of CD11b-
positive cells into adipose tissue [7]. In a pilot study, we
noticed, however, that in the retina, the expression of TNFa
and other inflammatory markers falls clearly below other
interesting factors and hence may be overestimated. We
therefore investigated in male aged obese ZDF rats and
lean littermates retinal morphology and, in parallel, asso-
ciated gene expression pattern by a novel method of par-
allel quantitative PCR in microfluidic cards. This
technology enables accurate assessment of abundance over
a wide dynamic range and, in parallel, regulation of genes
of interest. We selected genes of interest from published
sources with an emphasis on growth factors, inflammatory
markers, and adhesion molecules.
Methods
Zucker diabetic fatty (ZDF-Leprfa/Crl) rats were obtained
from Charles River Laboratories (Brussels, Belgium) in
two genotypes, obese ZDF (genotype Fa/Fa) and lean ZDF
littermates (genotype Fa/?) and kept under standard hous-
ing. The principles of laboratory animal care (NIH publi-
cation No. 86-23, revised 1985) were followed, as well as
the specific national law (the current version of the German
Law on the Protection of Animals) and further Sanofi
internal guidelines where applicable. Eight animals per
group were used in all subsequent analyses. Diabetes was
monitored weekly by blood glucose and insulin, and body
weight measurements.
Retinal preparation and quantification of morphometry
Retinal morphology was analyzed by retinal digest prepa-
rations and quantitative morphometry in 8-month-old ZDF
rats as described [8]. Briefly, after fixation of eyes in 4 %
PBS-buffered formaldehyde solution for 2 days, retinae
were isolated and then incubated with trypsin. Following a
periodic acid–Schiff (PAS)-hematoxylin staining, the
number of total pericytes was evaluated in ten randomly
selected fields per retina under 4009 magnification using
an image system and CellF analyzing software (Olympus,
Hamburg, Germany). The cell numbers were normalized to
relative capillary density (cell numbers/mm2 capillary
area). AC were counted under 409 objective with a sample
of PAS-stained retinal vasculature and normalized to rel-
ative retinal area (AC numbers/mm2 retinal area).
Gene expression measurements
Expression of several genes was quantified in parallel by
using TaqMan microfluidic card technology on an Applied
Biosystems ViiA7 cycler (software version 1.1). Retinal
RNA was isolated from individual retinas homogenized in
1 ml Trizol reagent (Invitrogen, Karlsruhe, Germany)
according to the manufacturer’s instructions. Crude RNA
was repurified using a RNeasy Mini Kit (Qiagen, Hilden,
Germany) followed by reverse transcription into cDNA
using a high-capacity kit (Life technologies, Darmstadt,
Germany). Samples were mixed with TaqMan Universal
PCR Master Mix (Life technologies, Darmstadt, Germany).
Ports of 384-well-format microfluidic cards were filled
with 100 ll sample solution, briefly centrifuged twice for
1,500X g, and sealed. Each 384-well microfluidic card
contained the specific TaqMan primers to detect 48 genes
(46 target genes and 2 housekeeping genes) for 16 samples
per plate. TaqMan primers were selected as the best cov-
erage for the specific genes, as recommended by the
manufacturer. For reference gene normalization, eukary-
otic 18S rRNA (Assay Hs99999901_s1) and beta-2-
microglobulin (B2 M, Rn00560865_m1) were selected.
Those reference genes were not found regulated in pilot
diabetes studies. In an initial step, the plate was heated to
95 C (1 C/s to 50 min, then 50 C for 2 min, 1 C/s to
95 C, then 95 C for 10 min). Subsequently, a real-time
PCR was performed with a maximum of 40 cycles each
consisting of sub-step 1 (95 C for 15 s, rapid cooling to
60 C with 1 C/s) and sub-step 2 (60 C for 1 min, then
rapid heating to 95 C with 1 C/s). A threshold quantifi-
cation cycle (Cq) was evaluated for each gene using the
manufacturer’s software. Stability of reference gene
expression, sample integrity, and differentially regulated
target genes were calculated using the BestKeeper-algo-
rithm, an Excel-based tool using pairwise correlations [9].
Relative target gene expression was finally calculated as
2^-DCq, with DCq being the difference between reference
median and target gene Cq value.
Statistics
Data were analyzed for normality and for homogeneous
variances (Levene). In case of Gaussian distributions,
ANOVA was employed. In case of heterogeneous vari-
ances and/or non-Gaussian distribution, a Kruskal–Wallis
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test was used. P values \0.05 were regarded as statistically
significant. Data are presented as mean ± SEM for gene
expression and mean ± SD for capillary and cell counts.
Results
At 3 months of age, male obese animals had developed
stable hyperglycemia (20.7 ± 1.3 mmol/L plasma glucose
vs. 6.5 ± 0.1 mmol/L in lean; P), which remained on this
plateau for the remaining 5 months of observation (Table 1).
Hyperinsulinemia initially present in obese rats at 2 months
(10.5 ± 0.7 lg/L plasma insulin vs 0.2 ± 0.04 lg/L in
lean) decreased due to ß-cell insufficiency at 3 months
(3.9 ± 0.6 vs. 0.5 ± 0.09 lg/ml in lean).
Retinal morphology assessed at 8 months of age revealed
an increase in the number of AC in obese (24 ± 5/mm2)
versus lean ZDF rats (15 ± 4/mm2, Fig. 1; Table 1). Peri-
cyte number was reduced by 28 % in obese (1,618 ± 241/
mm2) versus lean animals (2,238 ± 309/mm2), and endo-
thelial cell counts significantly increased by 16 %
(3,800 ± 438/mm2 in obese vs. 3,266 ± 415/mm2 in lean).
VEGFa, MIF, and HIF-1a were the most abundantly
expressed genes in retinas from both obese and lean ZDF
rats, but not differentially regulated (Fig. 2). bFGF (FGF2)
and placental growth factor (PGF) were significantly
expressed and up-regulated in diabetic animals (5.4X for
bFGF and 2.6X for PGF). Specific adhesion molecules,
ITGAM, ITGB2, and ICAM1, were found to be signifi-
cantly up-regulated in the diabetic environment. Nearly all
inflammatory genes in our set were either not expressed or
expressed at very low abundance. A significant up-regu-
lation on a very low expression level could be observed for




Fig. 1 Morphological changes in retina from aged male obese type-2
diabetic ZDF rats. a Representative PAS-stained retinas of lean and
obese ZDF rats. Red arrows point to AC. b Quantitative assessment of
AC. c and d. Count in pericytes and endothelial cells. E. Ratio of
endothelial cell to pericyte numbers. Asterisk denotes P \ 0.05 (color
figure online)
Table 1 Hyperglycemia, hyperinsulinemia and selected retinal parameters determined in the course of the study
Age 2 months 3 months 8 months
Biomarker Lean ZDF Obese ZDF Lean ZDF Obese ZDF Lean ZDF Obese ZDF
Blood glucose (mmol/L) 6.5 ± 0.1 13.6 ± 1.3 6.8 ± 0.1 20.7 ± 1.3 6.7 ± 0.1 22.4 ± 0.7
Plasma insulin (lg/L) 0.2 ± 0.04 10.5 ± 0.7 0.5 ± 0.09 3.9 ± 0.6 3.4 ± 0.2 3.8 ± 0.2
Number of retinal acellular capillaries (mm-2) n.d. n.d. n.d. n.d. 15 ± 4 24 ± 5
Number of retinal endothelial cells (mm-2) n.d. n.d n.d. n.d. 3,266 ± 415 3,800 ± 438
Number of retinal pericyte cells (mm-2) n.d. n.d. n.d. n.d. 2,238 ± 309 1,618 ± 241




Fig. 2 Quantitative assessment of gene expression by microfluidic card PCR. Relative expression to the geometric mean of three housekeeping
genes is given and categorized into high (a), medium (b), and low abundant (c) expression. Asterisk denotes P \ 0.05
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Discussion
Our study shows that in a rat model of type-2 diabetes,
retinal vasoregression associated with regulations in spe-
cific growth factors and adhesion molecules as reflected by
a quantitative gene expression protocol.
Strength of microfluidic card PCR technology is that
gene expression of a broader number of genes can be
rapidly quantified and compared with very high accuracy.
As a limitation, not all known genes can be assessed in an
unbiased manner, and hence, the pre-selection of genes to
be investigated is of utmost importance. We therefore
focused on genes, which have been described so far in
several models of diabetic retinopathy and compared
quantitatively their relative contribution in type-2-like
diabetic retinopathy.
In line with Behl et al. [4], we observed in aged male
obese ZDF rats an increased number of acellular retinal
capillaries and a pericyte dropout. These morphological
changes were similar to changes observed in type-1 dia-
betes models [10]. Among the investigated genes, only a
few are differentially regulated but those may hint to
important underlying molecular mechanisms.
Inflammatory genes such as TNFa, interleukin-1ß, and
inducible nitric oxide synthase were found to be expressed
at a low abundant level, supporting the view of a low-grade
inflammatory component. The simultaneous up-regulation
of the ITGAM/ITGB2 complex and ICAM-1 provides
evidence to an increased leukocyte recruitment process
[11]. As noted recently, these entrapped leukocytes may
directly damage retinal endothelial cells. However, the
overall contribution of leukostasis to retinal disease pro-
gression is questionable, since vasoregression can be pre-
vented by different treatment options without significant
reduction in leukostasis [12, 13].
High abundant expression was observed for all growth
factors investigated, but differential expression between
type-2 diabetic and non-diabetic animals could be observed
only for bFGF and PGF. Basic fibroblast growth factor
(FGF2) is constitutively expressed in the retina, and its
expression is increased by a microlesions but the role in
preclinical models of retinal vascularization is still uncer-
tain [14]. In clinical diabetic retinopathy, the normal retinal
distribution of bFGF changed during the development of
diabetic retinopathy and correlated with the onset of retinal
neovascularization [15]. bFGF was also involved in repair
of laser-induced retinal cell damage, suggesting that bFGF
represents, at least in part, a survival factor for damaged
neuroglial cells. Activity of PGF in diabetic retinopathy is
characterized marginally. Viral-mediated over-expression
of PGF in non-diabetic and diabetic rat retinas resulted in a
similar up-regulation as observed in our study and
contributed to capillary changes and blood–retinal barrier
breakdown [16].
Within our selection of genes, VEGF was the growth
factor with the highest expression but no significant dif-
ferential regulation. Others had demonstrated that VEGF
mRNA and protein expression is increased in retinae of
obese versus lean ZDF rats, albeit at younger disease age
and with only a modest up-regulation [6]. In our study, the
baseline expression of differentially regulated growth fac-
tors such as bFGF and PGF was 550X and 22X higher
compared to TNFa. Although this does not rule out any
role of low-grade inflammation in the disease progression,
it clearly demonstrates that future work should also focus
again on specific growth factors, bFGF and PGF, and their
contribution as pathological but also survival factors within
the retinal neurovascular units.
Even though the insulin level is close to be similar in the
diabetic versus non-diabetic rats at 8 months of age, the
number of AC and pericyte loss are significantly different
as is the blood glucose level. This is in accordance with
previous findings that glucose, but not insulin, may deter-
mine the biochemistry of microvascular damage (for a
review, see [17]). Furthermore, differences in pericyte loss
and vasoregression are more likely a consequence of
altered glucose-driven pathways than of insulin signaling
alterations [18]. It may be interesting to compare retinal
vasoregression in ZDF rats versus Zucker fatty rats (ZF
rats), which displays persistently high levels of insulin but
no hyperglycemia. If vasoregression indeed cannot be
identified in ZF rats, this would finally support the role of
hyperglycemia as initiating factor.
The finding that not VEGF but bFGF predominates in
the diabetic retina at this time point may be indicative of a
differential response to injury, combining the tissue
response to biochemical stress and the patterning of growth
factor expressions in various cells of the retina. Although
both VEGF and bFGF are predominantly expressed by
Mu¨ller cells, the temporal expression may vary. Further
studies including earlier time points may be helpful to
unravel differences in temporal expression patterns of
VEGF, bFGF, and PGF.
In summary, our study identified a strong expression
gradient of different genes involved in the pathogenesis of
diabetic retinopathy. Most of the inflammatory markers
were found at the low end of expression. Given this
interesting molecular patterning and reliable morphological
changes, we confirmed that male obese ZDF rats are suit-
able preclinical model for testing new therapeutic approa-
ches in diabetic retinopathy.
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